CREST Syndrome - a Limited Form of Systemic Scleroderma: a Case Report and Literature Review

1. Karadaglić Đ, Pavlović M. Sklerodermija. In: Karadaglć Đ, editor. Dermatologija. Beograd: Vojnoizdavački zavod, Versalpress Beograd; 2000. p. 1721-41.Search in Google Scholar

2. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 37-50.10.7326/0003-4819-140-1-200401060-00010Search in Google Scholar

3. Fabri M, Hunzelmann N. Differential diagnosis of scleroderma and pseudoscleroderma. J Dtsch Dermatol Ges 2007;5(11):977-84.10.1111/j.1610-0387.2007.06311.xSearch in Google Scholar

4. Mavrogeni S, Bratis C, Manoussakis M. Coronary artery abnormalities in CREST syndrome revealed by cardiovascular magnetic resonance imaging. Can J Cardiol 2011;27:390e5-7.10.1016/j.cjca.2010.12.052Search in Google Scholar

5. Tuffanelli DL, Winkelman RK. Diffuse systemic scleroderma. A comparison with acrosclerosis. Ann Intern Med 1962;57:198-203.10.7326/0003-4819-57-2-198Search in Google Scholar

6. Barnnett AJ. Scleroderma (progressive systemic sclerosis): progress and course based on a personal series of 118 cases. Med J Aust 1978;2:129-34.10.5694/j.1326-5377.1978.tb131413.xSearch in Google Scholar

7. Rodnan GP, Jablonska S, Medsger TA. Classification and nomenclature of progressive systemic sclerosis (scleroderma). Clin Rheum Dis 1979;5:5-13.10.1016/S0307-742X(21)00050-3Search in Google Scholar

8. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patient with scleroderma with various extent of skin sclerosis. J Rheumatol 1986;13:911-6.Search in Google Scholar

9. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.Search in Google Scholar

10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.Search in Google Scholar

11. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for scleroderma and sclerodermoid disorders. J Am Acad Dermatol 1996;35:609-14.10.1016/S0190-9622(96)90689-1Search in Google Scholar

12. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumtol 2001;28:1573-6.Search in Google Scholar

13. Poormoghim H, Lucas M, Fertig N, Medsger TA, Jr. Systemic sclerosis sine scleroderma: demographic, clinical and serologic features and survival in forty-eight patients. Arthritis Rheum 2000;43:444-51.10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-GSearch in Google Scholar

14. Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 2004;22(3 Suppl. 33):S5-13.Search in Google Scholar

15. Walker JG, Pope J, Baron M, LeClercq S, Hudson M, Taillefer S, et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 2007;26:1401-9.10.1007/s10067-007-0537-xSearch in Google Scholar

16. Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. Am Fam Psysican 2008;78(8):961-8.Search in Google Scholar

17. Habif TP, Campbell JL, Chapman MS, Dinulos JGH, Zug KA. Skin disease diagnosis and treatment. Philadelphia: Elsevier Mosby; 2005. p. 354-7.Search in Google Scholar

18. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008;37:223-35.10.1016/j.semarthrit.2007.05.003Search in Google Scholar

19. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laining TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.10.1002/art.11073Search in Google Scholar

20. Englert H, Joyner J, Bade R, Thompson M, Morris D, Chambers P, et al. Systemic scleroderma: a spatiotemporal clustering. Int Med J 2005;35:228-33.10.1111/j.1445-5994.2005.00783.xSearch in Google Scholar

21. Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991;283:366-71.10.1007/BF00371817Search in Google Scholar

22. Alamanos Y, Tsifetaki N, Voulgari PV. Epidemiology of systemic sclerosis in Northwest Greece 1981 to 2002. Semin Arthritis Rheum 2005;34:714-2010.1016/j.semarthrit.2004.09.001Search in Google Scholar

23. Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Reumatol 2006;33(5):1004-13.Search in Google Scholar

24. Tan FK. Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 2003;29:211-37.10.1016/S0889-857X(03)00015-2Search in Google Scholar

25. Radić M, Martinović Kaliterna D, Fabijanić D, Radić J. Sistemska skleroza-patogeneza, kliničke manifestacije i liječenje. Liječ Vjesn 2010;132:162-8.Search in Google Scholar

26. Yoon JC, Elston DM. CREST syndrome treatment and management. Medscape Drug, Disease and Procedures. [updated 2015 Oct 15; cited 2015 Oct 23]. Available from: http://emedicine.medscape.com/article/1064663-treatmentSearch in Google Scholar

27. Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology 2005;44:1212-6.10.1093/rheumatology/keh67115870151Search in Google Scholar

28. Herrik AL, Worthington A. Genetic epidemiology: systemic sclerosis. Arthritis Res 2002;4:165-8.10.1186/ar40212892712010566Search in Google Scholar

29. Gladman DD, Kung TN, Siannis F, Pellett F, Farewell VT, Lee P. HLA markers for susceptibility and expression in scleroderma. J Rheumatol 2005;32(8):1481-7.Search in Google Scholar

30. Del Rio APT, Sachetto Z, Sampaio-Barros PD, Marques-Neto JF, Santos Londe AC, Barros Bertolo M. HLA markers for poor prognosis in systemic sclerosis Brazilian patients. Dis Markers 2013;35(2):73-8.10.1155/2013/301415377495624167351Search in Google Scholar

31. Hartree N, Harding M, Jackson C. Systemic sclerosis (scleroderma). [cited 2015 Oct 1]. Available from: http://patient.info/doctor/systemic-sclerosis-sclerodermaSearch in Google Scholar

32. Limited scleroderma (CREST syndrome). ). [cited 2015 Oct 1]. Available from: http://www.mayoclinic.org/diseases-conditions/crest-syndrome/basics/definition/con-20031524Search in Google Scholar

33. Maitre A, Hours M, Bonneterre V, Arnaud J, Arslan MT, Carpentier P, et al. Systemic sclerosis and occupational risk factors: role of solvents and cleaning products. J Rheumatol 2004;31(12):2395-401.Search in Google Scholar

34. Bovenzi M, Barbone F, Pisa FE, Betta A, Romeo L, Tonello A, et al. A case-control study of occupational exposures and systemic sclerosis. Int Arch Occup Environ Health 2004;77:10-6.10.1007/s00420-003-0462-514530983Search in Google Scholar

35. Goodfield MJD, Jones SK, Veale DJ. The connective tissue diseases. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology. 8^th ed. London: Wiley-Blackwell; 2010. p. 51.64-51.79.Search in Google Scholar

36. Postiglione L, Montagnani S, Riccio A, Montuori N, Sciorio S, Ladogana P, et al. Enhanced expression of the receptor for granulocyte macrophage colony stimulating factor on dermal fibroblasts from scleroderma patients. J Rheumatol 2002;29(1):94-101.Search in Google Scholar

37. Thibierge G, Weissenbach R. Concretions calcaires souscutanées et sclerodermie. Ann Dermatol Syph 1911;4:129-55.Search in Google Scholar

38. Winterbauer RH. Multiple telangiectasia, Raynaud’s phenomenon, sclerodactyly, and subcutanious calcinosis: a syndrome mimicking hereditary hemorrhagic telangiectasia. Bull Johns Hopkins Hosp 1964;114:361-83.Search in Google Scholar

39. Frayha RA, Scarola JA, Hulman LE. Calcinosis in scleroderma: a reevaluation of the CREST syndrome (abstract). Arthritis Rheum 1973;16:542.Search in Google Scholar

40. Ensz S. Kidney (renal) involvement (main meni). International Scleroderma Network; c1998-2015 [cited 2015 Oct 1]. Available from: http://www.sclero.org/scleroderma/symptoms/renal/a-to-z.htmlSearch in Google Scholar

41. Goodfield MJ, Jones SK, Veale DJ. The connective tissue diseases. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s textbook of dermatology. 8^th ed. Oxford: Blackwell Publishing; 2010. p. 51.1-51.138.10.1002/9781444317633.ch51Search in Google Scholar

42. Robertson LP, Marshall RW, Hickling P. Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis Mar 2003;62(3):267-9.10.1136/ard.62.3.267175447912594118Search in Google Scholar

43. Kawakami T, Soma Y, Mizoguchi M, Saito R. Immunohistochemical analysis of transforming growth factor-beta 3 in calcinosis in a patient with systemic sclerosis and CREST syndrome. Br J Dermatol 2000;143:1097-131.10.1046/j.1365-2133.2000.03860.x11069531Search in Google Scholar

44. Merlino G, Germano S, Carlucci S. Surgical management of digital calcinosis in CREST syndrome. Aesthetic Plast Surg 2013;37:1214-9.10.1007/s00266-013-0224-z24142114Search in Google Scholar

45. Ngan V. Systemic sclerosis. Derm Net NZ c2003. [updated 2014 Dec 25; cited 2015 Oct 1]. Available from: http://www.dermnetnz.org/immune/systemic-sclerosis.html.Search in Google Scholar

46. Limited scleroderma (CREST syndrome). [cited 2015 Oct 1]. Available from: http://www.medicalgeek.com/disease-syndromes-procedures/15910-limited-scleroderma-crest-syndrome.html.Search in Google Scholar

47. Raynaud M. De l’asphyxie local de la gangrene symetrique des extremites. Paris: L. Leclerc; 1862.Search in Google Scholar

48. Paravina M. Bolesti vezivnog tkiva. In: Paravina M, Spalević Lj, Stanojević M. Tiodorović J, Binić I, Jovanović D. Dermatovenerologija. Niš: Prosveta; 2006. p. 219-28.Search in Google Scholar

49. Limited scleroderma (CREST syndrome). [cited 2015 Oct 1]. Available from: www.drugs.com/mcd/limited-scleroderma-crest–syndromeSearch in Google Scholar

50. CREST Syndrome. [cited 2015 Oct 1]. Available from: http://en.wikipedia.org/wiki/CREST-syndromeSearch in Google Scholar

51. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 2004;63:1009-14.10.1136/ard.2003.017673175514515308510Search in Google Scholar

52. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007;37:485-94.10.1111/j.1445-5994.2007.01370.x17547726Search in Google Scholar

53. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52:2125-32.10.1002/art.2113115986394Search in Google Scholar

54. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006;33: 269-74.Search in Google Scholar

55. Cox SR, Walker JG, Coleman M, Rischmueller M, Proudman S, Smith MD, et al. Isolated pulmonary hypertension in scleroderma. Inter Med J 2005;35:28-33.10.1111/j.1445-5994.2004.00646.x15667465Search in Google Scholar

56. Batal I, Domsic RT, Medsger TA, Bastacky S. Scleroderma renal crisis: a pathology perspective. Int J Rheumatol 2010;2010:543704.10.1155/2010/543704295849920981312Search in Google Scholar

57. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-3.10.7326/0003-4819-133-8-200010170-0001011033587Search in Google Scholar

58. Tarcin O, Tarcin O, Ozcivan M, Aydin H, Tiftikci A. CREST syndrome and Renal involvement. Marmara Med J 2007;20(3):186-9.Search in Google Scholar

59. Sugimoto T, Sanada M, Kashiwagi A. Is scleroderma renal crisis with anti-centromere antibody-positive limited cutaneous systemic sclerosis overlooked in patients with hypertension and or renal dysfunction? Nephrology 2008;13(2): 179-80.Search in Google Scholar

60. Sugimoto T, Soumura M, Soumura M. Scleroderma renal crisis in a patient with anticentromere antibody-positive limited cutaneous systemic sclerosis. Mod Rheumatol 2006;16(5):309-11.10.3109/s10165-006-0504-4Search in Google Scholar

61. Trang G, Steele R, Baron M, Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 2012;32(3):645-53.10.1007/s00296-010-1697-6Search in Google Scholar

62. Tojo J, Ohira H, Suzuki T, Takeda I, Shoji I, Kojima T, et al. Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms. Hepathol Res 2002;22:187-95.10.1016/S1386-6346(01)00138-3Search in Google Scholar

63. Kouraklis G, Glinavou A, Karatzas G. Primary biliary cirrhosis accompanied by CREST syndrome. South Med J 2002;95(9):1058-9.10.1097/00007611-200295090-00021Search in Google Scholar

64. Mavrogeni S, Manoussakis MN, Karagiorga TS, Douskou M, Panagiotakos D, Bournia V, et al. Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Arthitis Rheum 2009;61:1121-9.10.1002/art.2469519644909Search in Google Scholar

65. Mavrogeni S, Bratis C, Manoussakis M. Coronary artery abnormalities in crest syndrome revealed by cardiovascular magnetic resonance imaging. Can J Cardiol 2011; 27:390e5-7.10.1016/j.cjca.2010.12.05221474271Search in Google Scholar

66. Tzelepis GE, Kelekis NL, Plastiras SC, Mitseas P, Economopoulos N, Campolis C, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed-enhanced magnetic resonance imaging study. Arthritis Rheum 2007;56:3827-36.10.1002/art.2297117968945Search in Google Scholar

67. Lachter J, Suissa A, Schiff E, Rosner I. Anemia in CREST syndrome. Isr Med Assoc J 2003:5:449.Search in Google Scholar

68. Lauritano D, Bussolati A, Baldoni M, Leonida A. Scleroderma and CREST syndrome: a case report in dentistry. Minerva Stomatol 2011;60(9):443-65.Search in Google Scholar

69. Anastasopoulos G, Marinis A, Konstantinidis C, Theodosopoulos T, Fragulidis G, Vassiliou I. Adenocarcinoma of the third portion of the duodenum in a man with CREST syndrome. World J Surg Oncol 2008;6:106.10.1186/1477-7819-6-106256657318828905Search in Google Scholar

70. Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011;40:78-83.10.1007/s12016-010-8198-y20143182Search in Google Scholar

71. Haustein UF. Scleroderma and pseudoscleroderma: uncommon presentations. Clin Dermatol 2005;23:480-90.10.1016/j.clindermatol.2005.01.01916179182Search in Google Scholar

72. Mayes MD, Ho KT. Understanding and managing scleroderma. Scleroderma foundation. [cited 2015 Oct 1]. Available from: http://www.scleroderma.org/site/DocServer/UandM.pdf?docID=326Search in Google Scholar

73. Marangoni RG, Rocha LF, Del Rio AP, Yoshinari NH, Marquez-Neto JF, Sampaio-Barros PD. Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort. Rheumatology 2013;52:1520-4.10.1093/rheumatology/ket16323661427Search in Google Scholar

74. Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009:68:1878-84.10.1136/ard.2008.095836Search in Google Scholar

75. Lyons R, Narain S, Nichols C, Satoh M, Reeves WH. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Ann N Y Acad Sci 2005;1050:217-28.10.1196/annals.1313.023Search in Google Scholar

76. Nadashkevich O, Davis P, Fritzler MJ. A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 2004;10(11):CR615-21.Search in Google Scholar

77. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification criteria for systemic sclerosis: an American college of rheumatology / European league against rheumatism collaborative initiative. Artritis Rheumat 2013;65(11):2737-47.10.1002/art.38098Search in Google Scholar

78. Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, et al. Items for developing Revised Classification Criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care Res (Hoboken) 2012;64(3):351-7.10.1002/acr.20679Search in Google Scholar

79. Johnson SR, Fransen J, Khanna D, Baron M, van den Hogen F, Medsger TA Jr, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012;64(3):358-67.10.1002/acr.20684Search in Google Scholar

80. Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirjak L, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign suspicion of systemic sclerosis Ann Rheum Dis 2014;73(12):2087-93.Search in Google Scholar

81. Muller-Ladner U, Tyndall A, Czirjak L, Denton C, Matucci-Cerinic M, EUSTAR centres. Ten years EULAR Scleroderma Research and Trial (EUSTAR): what has been achieved? Ann Rheum Dis 2014;73(2):324-7.Search in Google Scholar

82. Khanna D, Furst DE, Allanore Y, Bae S, Bodukam V, Clements PJ, et al. Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology 2015;54:144-51.10.1093/rheumatology/keu288Search in Google Scholar

83. Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating The American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001;44(3):735-8.10.1002/1529-0131(200103)44:3<735::AID-ANR125>3.0.CO;2-FSearch in Google Scholar

84. Cutolo M, Matucci Cerinic M. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007;25:663-5.Search in Google Scholar

85. Jung P, Trautinger F. Capillaroscopy. J Dtsch Dermatol Ges 2013;11:731-6.10.1111/ddg.12137Search in Google Scholar

86. Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C. Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology (Oxford) 2006;45(Suppl 4):iv43-6.10.1093/rheumatology/kel310Search in Google Scholar

87. Baron M, Bell M, Bookman A, Buchignani M, Dunne J, Hudson M, et al. Office capillaroscopy in systemic sclerosis. Clin Rheumatol 2007;26:1268-74.10.1007/s10067-006-0489-6Search in Google Scholar

88. Hughes M, Moore T, O’Leary N, Tracey A, Ennis H, Dinsdale G, et al. A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis – spectrum disorders. Rheumatology 2015;54(8):1435-42.10.1093/rheumatology/keu53325749623Search in Google Scholar

89. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s ph enomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58(12):3902-12.10.1002/art.2403819035499Search in Google Scholar

90. Larche M. What’s new in Scleroderma. [cited 2015 Oct 1]. Available from: http://static1.squarespace.com/static/5280f5e9e4b0c046bfaad504/t/52decb0ee4b0fb2ead9eb0ba/1390332686069/Whats+new+in+Scleroderma+8th+Jan+2014.pdf.Search in Google Scholar

91. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.10.1016/j.semarthrit.2005.03.00516084222Search in Google Scholar

92. Karp DR, Marthandan N, Marsh SG, Ahn C, Arnett FC, Deluca DS, et al. Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis. Hum Mol Genet 2009;19(4):707-19.10.1093/hmg/ddp521280736519933168Search in Google Scholar

93. Arnett FC, Gourh P, Shete S, Ahn CW, Honey RE, Agarwal SK, et al. Major histocompability complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010;69(5):822-7.10.1136/ard.2009.111906291670219596691Search in Google Scholar

94. Loubiere LS, Lambert NC, Madeleine MM, Porter AJ, Mullarkey ME, Pang JM, et al. HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women. Rheumatology 2005;44(3):318-22.10.1093/rheumatology/keh48915572392Search in Google Scholar

95. Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007;357:1210-20.10.1056/NEJMoa06765517881752Search in Google Scholar

96. Beretta L, Rueda B, Marchini M, Santaniello A, Simeon CP, Fonollosa V, et al. Analysis of class II human leucocyte antigens in Italian and Spanish systemic sclerosis. Rheumatology 2012;51(1):52-9.10.1093/rheumatology/ker335327629322087014Search in Google Scholar

97. Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy 2010;2(6):863-78.10.2217/imt.10.69305951121091117Search in Google Scholar

98. Morita A, Kobayashi K, Isomura I, Tsuji T, Krutman J. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43:670-4.10.1067/mjd.2000.10516511004624Search in Google Scholar

99. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumathology 2005;44:145-50.10.1093/rheumatology/keh39015546967Search in Google Scholar

100. Goundry B, Bell L, Langtree M, Moorthy A, BMJ. Diagnosis and management of Raynaud’s phenomenon. BMJ 2012;344:e 289.10.1136/bmj.e28922315243Search in Google Scholar

101. Rybalkin SD, Yan C, Bornfeldt K, Beavo J. Cyclic phosphodiesterases and regulation of smooth muscle function. Circ Res 2003;93:280-91.10.1161/01.RES.0000087541.15600.2B12933699Search in Google Scholar

102. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005;64:1387.10.1136/ard.2004.034488175563316100356Search in Google Scholar

103. Rajagopalan S, Pfenninger D, Somers E, Kehrer C, Chakrabarti A, Mukherjee D, et al. Effects of Cilostazol in patients with Raynaud’s syndrome. Am J Cardiol 2003;92:1310-5.10.1016/j.amjcard.2003.08.01314636909Search in Google Scholar

104. Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, et al. Efficacy and tolerability of a selective alpha(2c)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004;50(12):3994-4001.10.1002/art.2066515593189Search in Google Scholar

105. Anderson ME, Moore TL, Hollis S, Jayson MIV, King TA, Herrick AL. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology (Oxford) 2002;41:324-8.10.1093/rheumatology/41.3.32411934971Search in Google Scholar

106. Cukierman T, Elinav E, Korem M, Chajek-Shaul T. Low dose warfarin treatment for calcinosis in patients with systemic sclerosis. Ann Rheum Dis 2004;63:1341-3.10.1136/ard.2003.014431175476915361398Search in Google Scholar

107. Sparsa A, Lesaux N, Kessler E, Bonnetblanc JM, Blaise S, Lebrun-Ly V, et al. Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy. J Am Acad Dermatol 2005;53:S263-5.10.1016/j.jaad.2005.04.01016227105Search in Google Scholar

108. Chamberlain AJ, Walker NP. Successful palliation and significant remission of cutanous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol Surg 2003;29:968-70.Search in Google Scholar

109. Saddic N, Miller JJ, Miller OF 3rd, Clarke JT. Surgical debridement painful fingertip calcinosis cutis in CREST syndrome. Arch Dermatol 2009;145:212-3.10.1001/archderm.145.2.212-b19221282Search in Google Scholar